To arrange an interview, please contact the NHLBI Communications Office at 301-496-4236 or email@example.com.
Michael Lauer, M.D., is the director of the Division of Cardiovascular Sciences at the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH). In this position, Dr. Lauer provides leadership for the Institute's national program for research on the causes, prevention, and treatment of cardiovascular (basic, clinical, population, and health sciences) diseases. Dr. Lauer joined the NHLBI in July 2007.
Dr. Lauer’s primary research interests include cardiovascular clinical epidemiology and comparative effectiveness, with a focus on diagnostic testing. He also has a strong background in leadership of the cardiovascular community and longstanding interests in medical editing—for seven years he was a contributing editor for Journal of the American Medical Association (JAMA) — and human subjects protection.
Prior to joining the NHLBI, Dr. Lauer served as the director of the Cleveland Clinic Foundation Exercise Laboratory and vice chair of the clinic's Institutional Review Board. He also served as co-director of the Coronary Intensive Care Unit and director of clinical research in the clinic's department of cardiology.
Dr. Lauer earned his Bachelor of Science degree in biology, summa cum laude, from Rensselaer Polytechnic Institute in 1983 and his Doctor of Medicine, magna cum laude, from Albany Medical College in 1985. Following internal medical training at the Massachusetts General Hospital, Harvard Medical School, he completed a clinical fellowship in cardiology at the Boston Beth Israel Hospital, Harvard Medical School. His further training in epidemiology included a research fellowship at the NHLBI’s Framingham Heart Study, Boston University; the program in clinical effectiveness, Harvard School of Public Health, Harvard University; and the Program for Physician Educators, Harvard Macy Institute.
Dr. Lauer is an elected fellow of the American College of Cardiology and American Heart Association, and has been elected to membership in the American Society for Clinical Investigation. He also served as chairman of the Exercise, Cardiac Rehabilitation, and Prevention Committee of the American Heart Association's Council of Clinical Cardiology, and has received numerous awards in recognition of his scientific and teaching accomplishments.
Areas of expertise: cardiovascular clinical epidemiology, comparative effectiveness research, and diagnostic testing
January 27, 2014
: The Plain Dealer
HDL, the "good" cholesterol, can be bad for your heart, Cleveland Clinic research shows
HDL, long known as “good” cholesterol for its tendency to help prevent the buildup of artery-clogging plaque, has a Jekyll and Hyde tendency to turn bad and cause damage that can lead to heart disease, according to NHLBI-supported research from the Cleveland Clinic published online today.
November 18, 2013
Renal artery stents lead to similar outcome versus medication-only
A commonly used stenting procedure to treat plaque build-up in the renal artery appears to offer no significant improvement when added to medication-based therapy, according to results from a National Institutes of Health-funded study. The narrowing and hardening of one or both renal arteries, known as renal artery stenosis, occurs in 1 to 5 percent of people who have high blood pressure, or hypertension.
Living With and Managing Coronary Artery Disease